NCT00762684View on ClinicalTrials.gov

Efficacy and Safety Study of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus

PHASE3TerminatedINTERVENTIONAL

Enrollment

8

Participants

Timeline

Start Date

November 30, 2004

Primary Completion Date

December 31, 2004

Study Completion Date

December 31, 2004

Conditions

Diabetes Mellitus

Interventions

DRUG

TAK-559

TAK-559 32 mg, tablets, orally, once daily for up to 26 weeks.

DRUG

Placebo

TAK-559 placebo-matching tablets, orally, once daily for up to 26 weeks.

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Takeda

INDUSTRY

NCT00762684 - Efficacy and Safety Study of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter